BiVictriX Therapeutics Plc announces that Dr. Michael Kauffman, M.D., Ph.D. has been appointed as Non-Executive Chairman. Dr. Kauffman takes over from Iain Ross, who will continue as a Non-Executive Director on the BiVictriX Board, but steps down as Chairman due to other work commitments. Prior to becoming Non-Executive Chairman, Dr. Kauffman was appointed as Non-Executive Director of BiVictriXin January 2022.

He is a highly experienced cancer drug developer, having been instrumental in the approval of several oncology therapeutics over twenty years of working across preclinical research, clinical development, regulatory strategy and commercialisation. As Non-Executive Chairman, he will draw upon his previous experience as Co-Founder and Chief Executive Officer of oncology company Karyopharm Therapeutics Inc., which he guided from a discovery stage biotechnology company to a commercial stage organisation, with global approvals of XPOVIO®.He also led the Kyprolis® development programme at Proteolix and then Onyx Pharmaceuticals, the Velcade® development programme at Millennium Pharmaceuticals, and has held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr. Kauffman currently holds other Non-Executive Board positions atVerastem Oncology, Adicet Bio and Kezar Life Sciences.